{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "This rule explicitly states that relevance is determined by the presence of client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase 3",
          "meta-analysis",
          "real-world data",
          "PROs",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Real-world evidence",
          "Treatment type"
        ],
        "contextual_concepts": [
          "patient reported outcomes",
          "registry studies"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "Requires both keyword and context matching for phases, real-world data, and treatment type; must exclude Ardelyx sponsored abstracts to be mutually exclusive with Internal."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored"
        ],
        "categories": [
          "Sponsorship"
        ],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "Can be identified by keyword matching for sponsorship."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Ardelyx sponsored abstracts and any abstracts qualifying for High priority",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints",
          "general study"
        ],
        "categories": [
          "Clinical trial phase",
          "Study type"
        ],
        "contextual_concepts": [
          "general studies",
          "outcomes and endpoints"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "Requires both keyword and context matching for study types and outcomes; must exclude Ardelyx sponsored and High priority abstracts for mutual exclusivity."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE Ardelyx sponsored abstracts and any abstracts qualifying for High or Medium priority",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "mention of indication without data"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PROs",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "Phase 1",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "trial outcomes",
        "endpoints",
        "general study"
      ],
      "reasoning": "Requires semantic/contextual analysis to determine if only indication is mentioned without any data; must exclude Ardelyx sponsored, High, and Medium priority abstracts for mutual exclusivity."
    }
  ]
}